The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is now priced at $1.94 and the shares are -0.03 points down or -1.52% lower compared to its previous closing price of $1.97. The stock had 2.598 million contracts set over the past session. MRNS shares’ daily volume is compared to its average trading volume at 1.749 million shares. However, it has a float of 82.92 million and although its performance was 1.57% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the MRNS share price recently placing at $1.89 to $2.08.

The shorts are climbing into the Marinus Pharmaceuticals, Inc. stock, with the latest data on short interest released on August 14, 2020, showing that short interest numbers in the MRNS shares have risen. Short interest in the stock represents just 13.74% of its float, but the volume has raised by 724268. The volume of shorted shares rised to 11.396 million from 10.672 million shares over the last two weeks. The average intraday trading volume has been 1.567 million shares, which means that days to cover moved to roughly 7.27191.

In the last trading session, Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) raised by $0.03 over the week and gained $0.26 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $3.5. The stock recorded its established 52-week high on 06/16/20.

Since 11/20/19, the stock has traded to a low of $1.01 at 92.08%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 1.94. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.

Looking at current readings, Marinus Pharmaceuticals, Inc.’s two-week RSI is 48.96. This suggests that the stock is neutral at the moment and that MRNS shares’ price movement remains stable. The stochastic readings are equally revealing at 37.41% meaning the MRNS share price is currently in neutral territory.

The technical chart shows that the MRNS stock will likely settle at between $2.05 and $2.16 per share. However, if the stock dips below $1.86, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $1.78.

Currently, the stock is trading in the red of MACD, with a reading of -0.0567. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.

Analysts at H.C. Wainwright though raised target price of MRNS stock from $6 to $9 but maintained Buy recommendation in their July 01 review. Cowen analysts see the stock as a Outperform in a flash note released to investors on July 01 initiating covering the stock. Craig Hallum analysts see the stock as Buy when the analysts initiated the share price coverage on April 09, placing it at $4.5.

The average rating for the MRNS equity is 1.44 and is currently gathering a bullish momentum. Of 9 analysts tracking Marinus Pharmaceuticals, Inc. polled by Reuters, 0 rated MRNS as a hold. The remaining 9 analysts were split evenly. However, the split wasn’t equal as a majority (9) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.